• Home
  • Cardiovascular diseases Publications

Cardiovascular diseases Publications

Cardiovascular diseases Publications

  • Patterns of antiplatelet drug use after a first myocardial infarction during a 10-year period.Abstract

    AIMS: The aims of the present study were to assess antiplatelet drug use patterns after a first myocardial infarction (MI) and to evaluate the determinants of antiplatelet nonpersistence. METHODS: The present study was conducted in 4690 patients frm the Utrecht Cardiovascular Pharmacogenetics cohort with a first MI between 1986 and 2010, who were followed for a maximum of 10 years

    Yasmina A, de Boer A, Deneer VH, Souverein PC, Klungel OH. Br J Clin Pharmacol. 2017 Mar; 83 632-641.
  • Characterization and cholesterol management in patients with cardiovascular events and/or type 2 diabetes in the Netherlands.Abstract

    OBJECTIVE: To describe clinical characteristics and cholesterol management of patients with cardiovascular events (CVEs) and/or type 2 diabetes mellitus (T2DM) with high low-density lipoprotein cholesterol (LDL-C) > 1.8 mmol/L in the Netherlands. RSEARCH DESIGN AND METHODS: From the PHARMO Database Network a cross-sectional cohort was constructed

    Heintjes E, Kuiper J, Lucius B, Penning-van Beest F, Kutikova L, Liem A, Herings R. Curr Med Res Opin. 2017 Jan; 33 91-100.
  • Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts.Abstract

    BACKGROUND: Preclinical studies have demonstrated that propranolol inhibits several pathways involved in breast cancer progression and metastasis. We investigated whether breast cancer patients who used propranolol, or other non-selective beta-blocers, had reduced breast cancer-specific or all-cause mortality in eight European cohorts

    Cardwell CR, Pottegard A, Vaes E, Garmo H, Murray LJ, Brown C, Vissers PA, O'Rorke M, Visvan athan K, Cronin-Fenton D, DeSchutter H, Lambe M, Powe DG, van Herk-Sukel MP, Gavin A, Friis S, Sharp L, Bennett K. Breast Cancer Res. 2016 Dec 01; 18 119.
  • Cardiovascular medication use and cardiovascular disease in children and adolescents with type 1 diabetes: a population-based cohort study.Abstract

    OBJECTIVES: To investigate the 5-yr prevalence and incidence rates of cardiovascular medication and cardiovascular disease before and after onset of type 1 diabetes (T1D) in children and adolescents. METHODS: Children and adolescents (<19 yr) with1D (n = 925), defined as those who received at least two insulin prescriptions, and a four times larger reference cohort (n = 3591) with the same age and gender in the Dutch PHARMO Record Linkage System (RLS) were studied in a retrospective cohort studybetween 1999 and 2009

    Ahmadizar F, FazeliFarsani S, Souverein PC, van der Vorst MM, deBoer A, Maitland-van der Zee AH. Pediatr Diabetes. 2016 Sep; 17 433-40.
  • Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel-proton pump inhibitor interaction.Abstract

    Safety concerns of the concomitant use of clopidogrel-proton pump inhibitors (PPIs) were published in 2009 and 2010 by the medicines regulatory agencies, including a direct healthcare professional communication. We examined the association between various safety statements and prescription behavior for gastroprotective drugs in naive patients in the Netherlands during the years 2008-2011

    Pharmacology Research & Perspectives. July 18; 4 e00242.
  • Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study.Abstract

    Analyses of healthcare data from 30 million individuals in three countries showed that current use of bisphosphonates may be associated with a small increased risk of cardiac valvulopathy (vs. those not exposed within the previous year), although cnfounding cannot be entirely ruled out. The observed tendency for decreased valvulopathy risk with cumulative duration of bisphosphonate use >6 months may even indicate a protective effect with prolonged use

    Coloma PM, deRidder M, Bezemer I, Herings RM, Gini R, Pecchioli S, Scotti L, Rijnbeek P, Mosseveld M, van der Lei J, Trifiro G, Sturkenboom M, Consortium Eu-Adr. Osteoporos Int. 2016 May; 27 1857-67.
  • Oral and inhaled corticosteroid use and risk of recurrent pulmonary embolism.Abstract

    INTRODUCTION: Chronic inflammatory diseases predispose for development of a first pulmonary embolism (PE). Previous studies showed that corticosteroids, which are the mainstay of treatment for inflammatory diseases, enhance the risk of a first venos thromboembolism. Yet, it is unknown whether corticosteroids also predispose for recurrent events

    Sneeboer MM, Hutten BA, Majoor CJ, Bel EH, Kamphuisen PW. Thromb Res. 2016 Feb 12; 140 46-50.
  • Explaining the Decline in Coronary Heart Disease Mortality in the Netherlands between 1997 and 2007.Abstract

    OBJECTIVE: We set out to determine what proportion of the mortality decline from 1997 to 2007 in coronary heart disease (CHD) in the Netherlands could be attributed to advances in medical treatment and to improvements in population-wide cardiovascuar risk factors. METHODS: We used the IMPACT-SEC model

    Koopman C, Vaartjes I, van Dis I, Verschuren WM, Engelfriet P, Heintjes EM, Blokstra A, Deeg DJ, Visser M, Bots ML, O'Flaherty M, Capewell S. PLoS One. 2016 11 e0166139.
  • Anticoagulant Treatment after VTE in the Netherlands: A Retrospective Cohort Study.Abstract

    Background: The aim of the study was to describe initial anticoagulant treatment after venous thromboembolism (VTE) and relate this to the underlying risk factors, guidelines and recurrence rates.

    Bezemer ID, van den Berg EJ, Herings RMC, Bamber L, Penning-van Beest FJA, Folkerts K, Coppens M. J J Hemato. 2016 2 030.
  • Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study.Abstract

    OBJECTIVES: To investigate the cardiovascular safety of non-steroidal anti-inflammatory drugs (NSAIDs) and estimate the risk of hospital admission for heart failure with use of individual NSAIDs. DESIGN: Nested case-control study. SETTING: Five poplation based healthcare databases from four European countries (the Netherlands, Italy, Germany, and the United Kingdom)

    Arfe A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V, Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G, SafetyofNon-steroidalAnti-inflammatoryDrugsProject Consortium. BMJ. 2016 354 i4857.